Pembrolizumab Shows Activity Among Some Young Patients With Advanced Sarcoma

Share this content:
PD-1 inhibition with pembrolizumab may be an effective treatment option for adolescent and young adult patients with some sarcoma subtypes.
PD-1 inhibition with pembrolizumab may be an effective treatment option for adolescent and young adult patients with some sarcoma subtypes.
The following article features coverage from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Click here to read more of Cancer Therapy Advisor's conference coverage.

PD-1 inhibition with pembrolizumab may be an effective treatment option for adolescent and young adult patients with some sarcoma subtypes, according to a study presented at the 2017 American Society of Clinical Oncology (ASCO) meeting in Chicago, Illinois.1

Among adolescents and young adults with cancer, 10% to 15% have sarcoma, which carries a poor prognosis after metastasis or relapse.

For this retrospective analysis, researchers reviewed data from 14 adolescent and young adult patients with sarcoma to determine whether PD-1 inhibition is an effective strategy in this setting.

All patients had advanced bone/tissue sarcoma and received pembrolizumab 2 mg/kg intravenously every 21 days. Patients were self-funded.

The median age was 24 (range, 14 to 35), 7 were male and 7 female, and the Eastern Cooperative Oncology Group (ECOG) performance scores were 0 to 1 in 6 patients, 2 in 6 patients, and 3 to 4 in 2 patients.

Three patients had osteosarcoma, 5 had Ewing sarcoma, 2 had synovial sarcoma, 2 had alveolar soft part sarcoma, 1 had embryonal rhabdomyosarcoma, and 1 had and clear cell sarcoma.

All patients were treated between May 2015 and December 2016. The median follow-up was 4 drug doses, though 3 patients died prior to assessment.

An “excellent, sustained response” was observed in 1 patient with Ewing sarcoma. Both patients with alveolar soft part sarcoma responded, 1 with an “excellent clinical response” and 1 with stable disease. All other patients had progressive disease.

RELATED: Potential Clinical Benefit in Multigene Hereditary Testing for Patients With Sarcoma

No grade 3 or worse adverse events were observed.

The authors concluded that these “data suggest further evaluation of the role of pembrolizumab in [adolescent and young adult] patients with advanced sarcoma is warranted.”

Read more of Cancer Therapy Advisor's coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting by visiting the conference page.

Reference

  1. Scheinberg T, Lomax A, Tattersall MH, et al. PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma. J Clin Oncol. 2017;35(suppl; abstr 3060).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters